Compare Gilead Sciences, Inc. (GILD) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Toyota Motor Corp — how do they compare? Gilead Sciences, Inc. trades at $135.83 (market cap $163.51B), while Toyota Motor Corp trades at $179.63 (market cap $210.48B). The key difference: Toyota Motor Corp is the larger of the two by market cap, and Toyota Motor Corp pays the higher dividend (3.54%). Which is the better fit depends on your goals.
| GILD | TM | |
|---|---|---|
Market Cap | $163.51B | $210.48B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $248.29 |
52-Week Low | $108.22 | $166.50 |
Enterprise Value | $178.05B | $374.67B |
Dividend Yield | 2.49% | 3.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Toyota Motor (TM) trades at $179.34, up 1.77% today, with a neutral technical signal and bullish moving averages. The stock shows strong fundamentals with a P/E of 9.69 and consistent earnings beats, including Q1 2026 EPS of $4.00 versus $3.11 expected. Recent news highlights a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling growth commitment.
TM presents a value opportunity with attractive valuation ratios and solid profitability, but faces risks from competitive pressures and fluctuating net income margins. Analyst consensus is mixed with 37.5% buy ratings, indicating cautious optimism. The stock's outlook hinges on successful execution of US manufacturing investments and hybrid vehicle demand amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
